IPO
NEUTRALPulmocide terminates Phase 3 study for Opelconazole
The biopharmaceutical company Pulmocide has announced the termination of its Opera-T Phase 3 study with opelconazole in refractory Invasive Pulmonary Aspergillosis.
IP Group
57.30GBX
-3.37%
Market Cap
506.20M
Volume
3.56M
90% of avg
P/E Ratio
722.12
EPS (TTM)
0.08
Beta
1.38
Day Range
56.10p - 60.10p
52 Week Range
34.35p57.30p66.16p
57.30p
Upcoming Events
March 17, 2026
Expected date for full year 2025 results announcement
High Impact Event
Late 2027
Target for delivering over £250m of exits
High Impact Event
IPO
NEUTRALIP Group Plc Announces Holding(s) in Company
The asset management firm has disclosed changes to its major shareholdings in IP Group Plc.
IPO
NEUTRALIP Group Plc Announces Change in Shareholding
The investment firm has disclosed a change in its shareholding in IP Group Plc.
IPO
NEUTRALIP Group Plc Announces Change in Shareholding
The asset management firm has announced a change in shareholding, with BlackRock, Inc. increasing its stake in the company.
IPO
NEUTRALIP Group Plc Announces Holding(s) in Company
The financial services firm has disclosed a change in its shareholding position in IP Group Plc.
IPO
NEUTRALIP Group Plc Announces Change in Shareholding
The financial services firm has disclosed a change in its shareholding structure.
IPO
NEUTRALIP Group Completes £75m Share Buyback Programme
The asset management firm has successfully completed a £75m share buyback programme.
IPO
GOODIP Group-backed Artios Pharma secures $115m in oversubscribed financing round
The biopharmaceutical company has raised $115 million in an oversubscribed financing round to advance its clinical programs, with IP Group increasing its stake in the business.
IPO
NEUTRALIP Group Plc Announces Holding(s) in Company
The asset management firm has disclosed changes to its major shareholdings.
IPO
NEUTRALIP Group Plc Announces Change in Shareholding
The investment firm has disclosed a change in its shareholding in IP Group Plc.